FDA Approves Dainippon Sumitomo Schizophrenia Drug Lurasidone
This article was originally published in PharmAsia News
U.S. FDA approved atypical antipsychotic Latuda (lurasidone) for schizophrenia
You may also be interested in...
Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.
The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.